MDimune Selected by Lonza to the Startup Creasphere Program
Total of 11 startups have been selected to the Batch 5 of Startup Creasphere
The Startup Creasphere program is hosted twice a year by Plug and Play, the world's largest startup incubator. The program partners numerous startups with global corporations such as Microsoft, Bill & Melinda Gates Foundation, Accenture, UKSH, Roche, Sanofi, and Lonza. The startups go through a close examination of their technology, marketability, and growth potential in various fields, including healthcare, artificial intelligence (AI), mobile, and media worldwide.
During the kick-off meeting held on Oct 22, 2020, Lonza shared their company's roadmap for improved drug delivery and their strategies to overcome current hurdles of exosome research before MDimune was introduced in conjunction with them. "They have developed a drug delivery platform called BioDrone® Platform that yields 10-30 times higher production rate as compared to normal exosomes," said Fabian Schugenflug of Plug and Play as he introduced MDimune. Then, Seung Wook Oh, Ph.D., Chief Scientific Officer (CSO) of MDimune, presented the prospects of the BioDrone® platform technology.
“BioDrone® is a platform technology with excellent versatility and expandability. By combining numerous technologies to allow efficient drug loading and targeting, this platform can be applied to address diverse human diseases. The collaboration with a prestigious company like Lonza will escalate the BioDrone® platform to the level closer to commercialization,” said Dr. Oh.
BioDrone® is an innovative technology that relies on cell-derived vesicles (CDVs) to achieve highly target-specific drug delivery. The BioDrone® platform technology is patented in the US, Europe, China, Japan, and Korea. The South Korean company also prepares to go public with an IPO in the second half of 2021.
About MDimune Inc.
Founded in 2015, MDimune has been dedicated to the development of innovative therapeutic platform called BioDrone®. BioDrone® platform technology is a novel technology that uses cell-derived vesicles (CDVs) to achieve highly target-specific drug delivery. The BioDrone® platform technology is patented in the US, Europe, China, Japan, and Korea. MDimune’s current focus includes cancer, COPD, OA and other rare diseases. MDimune is actively pursuing business partnerships with biotech, pharmaceuticals, and hospitals for the potential application of the BioDrone® technology in various unmet medical needs.
Summer Lee
MDimune Inc.
+82 -10-3789-3589
email us here
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
